
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a regenerative medicine company operating in a single segment. The company's diverse product portfolio has a strong foothold in the skin substitute segment of the advanced wound care market. However, CMS reimbursement changes have impacted the industry, leading to a decline in revenue in 2026. Despite this challenge, Organogenesis has a significant potential for growth in the long term due to the increasing demand for advanced wound care technologies and the company's unique product offerings. As a result, the company's stock is currently trading at a discounted price compared to its peers, presenting a good opportunity for investment.
Bears say
Organogenesis Holdings is facing numerous challenges in its market segment and business model which are negatively impacting its financial performance. The company has a pureplay exposure to reimbursement, which is a major concern in the regenerative medicine market. The recent reimbursement cuts have resulted in a seismic decline in the end market for the company, with an estimated 60-90% reduction in demand. This has been further exacerbated by a wastage ruling that is disproportionately impacting one of Organogenesis's key products, Apligraf, leading to a negative economic incentive for its use. These factors have led to a significant decline in the company's revenue and profitability, and while there is potential for growth in the long term, the uncertainty and ongoing shifts in the market make it difficult to predict when this will be realized. Additionally, the company's potential new product, ReNu, represents a binary outcome with FDA decision and would only contribute to revenue and profitability in 2028 at the earliest.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares